ストックスクリーナーアプリを入手
0.00
100.00%
-28.56
アフターアワーズ：
27.86
27.86
+
Vyne Therapeutics Inc (VYNE) 最新ニュース
Vyne Therapeutics Inc (NASDAQ: VYNE) Share Price, VYNE Stock News, VYNE Share Price & Updates - Kalkine
VYNE Therapeutics (VYNE) Holds Flat at $28.56 as Shares Sit Mid-Range Between Key Technical Levels - dars.gov.et
VYNE stock holds at $28.56 as investors await the next data catalyst - AD HOC NEWS
VYNE Special Dividend Tied To Merger: My Take On The 8-K Learn (V8sbUVk4ib) - Mshale
VYNE (VYNE) Levels: Trades in a Narrow Directional Range at $28.56 in the Latest Session; Technical Setup: $27.13 and $29.99 Define the Nearby Reference Levels in Latest TradingVolatility Term Structure - vinanet.vn
VYNE (VYNE) Trading-Day Recap: Closes with Limited Movement at $28.56 in the Current Update; Price-Level Context: Price Remains Between $27.13 Support and $29.99 Resistance in Latest TradingSynthetic Long - vinanet.vn
Rachael Alford Net Worth (2026) - GuruFocus
Lori Payton Net Worth (2026) - GuruFocus
New Haven biotech goes public after merger, raises $200M - Hartford Business Journal
VYNE Therapeutics (VYNE) Consolidates at $28.56 as Key Support and Resistance Levels Define Trading RangeTrade Entry Signals - vinanet.vn
Yarrow Bioscience (VYNE) halves losses and completes transformative merger with Yarrow - Stock Titan
Yarrow Bioscience Reports Second Quarter 2026 Financial Results and Provides Business Update - BioSpace
ORBIMED ADVISORS LLC Buys VYNE Therapeutics Inc (VYNE) -- Shares Look 27% Overvalued on GF Value - GuruFocus
VYNE Q1 2026 Earnings: Narrower-Than-Expected -$4.00 Per Share Loss Delivers 56.43% Surprise - vinanet.vn
Top Portage Biotech (ALP) Competitors 2026 - MarketBeat
Yarrow Bioscience (VYNE): Logos group discloses 10.7% ownership and large warrants - Stock Titan
OrbiMed Advisors Discloses Investment at Yarrow Bioscience with 9.97% Stake - TradingView
OrbiMed discloses sub-10% Yarrow Bioscience, Inc. (Ticker: VYNE) stake and large warrants - Stock Titan
Yarrow Bioscience (VYNE) sees 9.9% ownership stake from Logos Global funds - Stock Titan
Biotech Stocks At 52-Week HighsANGO, ANIK, ELOX, YARW, PLSE - RTTNews
VYNE Q1 2026 Earnings: Narrower-Than-Expected Loss Delivers 56.43% Positive SurpriseEarnings Manipulation Risk - vinanet.vn
RTW group discloses 266,307-share, 9.99% holding in Yarrow Bioscience (VYNE) - Stock Titan
Vyne Therapeutics issues pre-funded warrants for 133,290 shares in stock exchange deal - Bitget
Yarrow Bioscience (YARW) Stock Price, News & Analysis - MarketBeat
Yarrow Bioscience, Inc. (VYNE) director reports large OrbiMed warrants - Stock Titan
YARWYarrow Bioscience Inc Stock Price and Quote - Finviz
Yarrow Bioscience closes VYNE merger and $200 million financing - Quiver Quantitative
Net income before discontinued operations of VYNE Therapeutics Inc. – NASDAQ:YARW - TradingView
VYNE Therapeutics Inc. Earnings and Revenue – NASDAQ:YARW - TradingView
VYNE Therapeutics Inc. Balance Sheet – NASDAQ:YARW - TradingView
Vyne Therapeutics Inc (VYNE) Institutional Confidence - TradingKey
Yarrow Bioscience Completes VYNE Therapeutics Merger, Begins Phase 2 Trial Dosing for YB-101 - Moomoo
Yarrow Bioscience Announces Closing of Merger with VYNE Therapeutics and Initiation of Dosing in Phase 2a/2b Trial of YB-101, a Potential First-in-Class Treatment for Graves’ Disease and Thyroid Eye Disease - Business Wire
VYNE|Vyne Therapeutics Inc|Price:0.509|Chg%:-0.012 - TradingKey
VYNE|Vyne Therapeutics Inc|Price:28.560|Chg%:+28.051 - TradingKey
Yarrow Bioscience Completes VYNE Merger and Nasdaq Debut - TipRanks
Vyne Therapeutics Inc (VYNE) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
VYNE|Vyne Therapeutics Inc|Price:28.560| - TradingKey
Vyne Therapeutics Inc (VYNE) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Vyne Therapeutics Inc (VYNE) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
TradingKey - TradingKey
VYNE Q1 2026 Earnings: EPS Beats Estimates Amid Steep Stock DeclineRevenue Miss Report - vinanet.vn
Vyne Therapeutics Provides Update Regarding C - Moomoo
Form 4 Vyne Therapeutics Inc For: 24 July By Investing.com - Investing.com Nigeria
VYNE Therapeutics (Ticker: VYNE) CFO reports tax-share withholding event - Stock Titan
Tax withholding trims stake of VYNE Therapeutics Inc. (VYNE) CSO - Stock Titan
VYNE Therapeutics (VYNE) CLO has shares withheld for RSU taxes - Stock Titan
VYNE Therapeutics Inc. Revenue Breakdown – NASDAQ:VYNE - TradingView
VYNE Therapeutics Provides Update Regarding Cash Dividend, Reverse Stock Split and Anticipated Timing of Closing of the Proposed Merger with Yarrow Bioscience - marketscreener.com
Press Release: VYNE Therapeutics Provides Update Regarding Cash Dividend, Reverse Stock Split and Anticipated Timing of Closing of the Proposed Merger With Yarrow Bioscience - Moomoo
VYNE Therapeutics To Go Ex-Dividend On July 24th, 2026 With 0.40242 USD Special Dividend Per Share - Moomoo
VYNE distributes special cash dividend, merger closing delayed - Investing.com
VYNE Therapeutics (NASDAQ:VYNE) Draws Technical Attention After Reverse Split Update - Kalkine Media
VYNE Therapeutics Announces 1-for-50 Reverse Stock Split, $17.3M Special Dividend, and Merger with Yarrow Bioscience – Minichart - minichart.com.sg
Vyne Therapeutics Announces Aggregate Cash Div of $17.3M, or Abput $0.40242 Per Shr >VYNE - Moomoo
VYNE Therapeutics approves 1-for-50 reverse stock split - Investing.com
VYNE Therapeutics approves 1-for-50 reverse stock split By Investing.com - Investing.com Australia
VYNE Therapeutics approves 1-for-50 reverse stock split ahead of Yarrow merger - MSN
VYNE Therapeutics Announces Reverse Split and Merger Plans - TipRanks
VYNE Therapeutics announces 1-for-50 reverse stock split - TipRanks
VYNE Announces 1-for-50 Reverse Stock Split, $17.3M Special Cash Dividend Ahead of Yarrow Merger - TradingView
VYNE Therapeutics Announces 1-for-50 Reverse Stock Split and Provides Update Regarding Special Dividend in Connection with the Proposed Merger with Yarrow Bioscience - marketscreener.com
Press Release: VYNE Therapeutics Announces 1-for-50 Reverse Stock Split and Provides Update Regarding Special Dividend in Connection With the Proposed Merger With Yarrow Bioscience - Moomoo
0.14%
0.15%
大文字化:
|
ボリューム (24 時間):